EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Epilepsy‐Desirability of Outcome Ranking ( DOOR ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials

Lucy Vivash iD, Hannah Johns, Terence J O Brien, Leonid Churilov

European Journal of Neurology · 2026

DOI: 10.1111/ene.70531 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Lucy Vivash und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Epilepsy, Outcome Assessment, Health Care. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New drug trials in drug resistant epilepsy are typically powered to detect changes in seizure frequency as the primary endpoint, without integrating other treatment‐associated benefits and harms. We developed Epilepsy‐DOOR, a consumer‐codesigned outcome measure, which combines seizure frequency with quality of life and adverse event measures. This study evaluated Epilepsy‐DOOR in previously completed phase 3 clinical trials of adjunctive brivaracetam in patients with drug resistant epilepsy.

Methods

Epilepsy‐DOOR was derived for each participant who completed the randomised controlled trial of three Phase 3 trials of brivaracetam (N01252, N01253, N01254). Win odds were estimated for Epilepsy‐DOOR and its individual components: change in seizure frequency, quality of life, and adverse event severity for treatment with brivaracetam over placebo for each dose in each study. Odds ratio was estimated for responder rate.

Results

In N01252, Epilepsy‐DOOR demonstrated benefit of 100 mg brivaracetam (Win odds 1.42, 95% CI 1.03, 1.97) but not smaller doses over placebo, in line with the results when using responder rate (odds ratio 1.14, 95% CI 1.02, 1.29). In studies N01253 and N01254, benefit as assessed by Epilepsy‐DOOR did not attain statistical significance, despite benefits at some doses when measuring seizure responder rate.

Conclusion

Epilepsy‐DOOR showed similar effect sizes but slightly reduced power when compared with responder rate. This reduced power is due to the appropriate reflection of adverse events by Epilepsy‐DOOR. Epilepsy‐DOOR provides a more holistic measure of anti‐seizure medication treatment effects, balancing relative benefits and harms, and has potential as a future endpoint in clinical trials in epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsDrug Resistant EpilepsyEpilepsyOutcome Assessment, Health CarePyrrolidinonesAdultFemaleHumansMaleMiddle AgedQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

consumer designepilepsyinterventional clinical trialtrial outcomes

Substanzen

AnticonvulsantsbrivaracetamPyrrolidinones

Autor:innen und Institutionen

  • Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia.
  • Department of Neurology, Alfred Health, Melbourne, Australia.
  • Department of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, Australia.
  • Department of Neurology, Royal Melbourne Hospital, Parkville, Australia.

ORCID-Profile: Lucy Vivash

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Vivash, L., Johns, H., O Brien, T. J., & Churilov, L. (2026). The Epilepsy‐Desirability of Outcome Ranking ( DOOR ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials. European Journal of Neurology. https://doi.org/10.1111/ene.70531

Vancouver

Vivash L, Johns H, O Brien TJ, Churilov L. The Epilepsy‐Desirability of Outcome Ranking ( DOOR ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials. European Journal of Neurology. 2026. doi:10.1111/ene.70531

BibTeX
@article{Vivash2026,
  author = {Vivash, Lucy and Johns, Hannah and O Brien, Terence J and Churilov, Leonid},
  title = {The Epilepsy‐Desirability of Outcome Ranking ( DOOR ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70531}
}
Kostenlos starten →